{"id":"budecort-aqua","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nasal irritation"},{"rate":null,"effect":"Epistaxis"},{"rate":null,"effect":"Throat irritation"},{"rate":null,"effect":"Candidiasis (oral/pharyngeal)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Budesonide, the active ingredient, is a selective glucocorticoid receptor agonist that suppresses inflammatory cytokine production and immune cell recruitment in the airways. When delivered as an aqueous nasal or inhaled spray formulation, it provides topical anti-inflammatory effects with minimal systemic absorption, reducing airway edema, mucus production, and bronchial hyperresponsiveness.","oneSentence":"Budecort Aqua is an inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors in lung tissue.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:55:06.067Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Allergic rhinitis"},{"name":"Asthma (maintenance therapy)"}]},"trialDetails":[{"nctId":"NCT03755557","phase":"PHASE3","title":"Demonstration of Equivalence and Early Onset of a Novel Anti-allergic Nasal Spray Compared to Marketed Nasal Spray","status":"COMPLETED","sponsor":"Marinomed Biotech AG","startDate":"2018-11-19","conditions":"Allergic Rhinitis, Allergic Conjunctivitis, Hayfever","enrollment":82},{"nctId":"NCT02972866","phase":"PHASE3","title":"Clinical Study, Non Inferiority Between Noex® 32µg Versus Budecort Aqua® 32µg in Treatment of Alergic Rhinitis","status":"WITHDRAWN","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2016-06","conditions":"Rhinitis, Allergic, Perennial","enrollment":""},{"nctId":"NCT01089647","phase":"PHASE3","title":"Montelukast and Inhaled Nasal Steroid Tx in Adult Obstructive Sleep Apnea (OSA)","status":"COMPLETED","sponsor":"Romaker & Associates","startDate":"2010-09","conditions":"Obstructive Sleep Apnea","enrollment":34},{"nctId":"NCT02668861","phase":"PHASE3","title":"Effect of Oral Vitamin D3 on Chronic Rhinosinusitis Treatment in Adults With Lower Vitamin D Levels","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Shanxi Medical University","startDate":"2016-05","conditions":"Chronic Rhinosinusitis With Nasal Polyps","enrollment":40},{"nctId":"NCT00321893","phase":"PHASE2","title":"Budesonide in Treating Patients With Lung Nodules at High Risk of Developing Lung Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2006-01","conditions":"Lung Cancer","enrollment":225},{"nctId":"NCT01022047","phase":"PHASE3","title":"Non-inferiority, Open-label, Multicenter and Randomized Clinical Trial About the Treatment of Mild to Moderate Persistent Allergic Rhinitis","status":"COMPLETED","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2010-02","conditions":"Allergic Rhinitis","enrollment":280},{"nctId":"NCT00940953","phase":"PHASE2","title":"Compare Captisol-Enabled (CE) Budesonide + Azelastine Nasal Solution and Rhinocort Aqua + Astelin in an Environmental Exposure Chamber (EEC) Study of Allergic Rhinitis","status":"COMPLETED","sponsor":"Ligand Pharmaceuticals","startDate":"2008-02","conditions":"Seasonal Allergic Rhinitis","enrollment":108},{"nctId":"NCT00938613","phase":"PHASE2","title":"Compare CE-Budesonide Nasal Solution & Rhinocort Aqua in an EEC Study of AR","status":"COMPLETED","sponsor":"Ligand Pharmaceuticals","startDate":"2007-02","conditions":"Seasonal Allergic Rhinitis","enrollment":65},{"nctId":"NCT00641680","phase":"PHASE3","title":"Rhinocort Aqua Versus Placebo and Fluticasone Propionate","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-04","conditions":"Seasonal Allergic Rhinitis","enrollment":750},{"nctId":"NCT00641693","phase":"PHASE2","title":"Assess the Efficacy and Safety of Rhinocort Aqua","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-04","conditions":"Allergic Rhinitis","enrollment":650},{"nctId":"NCT00641979","phase":"PHASE2","title":"New Nasal Applicator / New Formulation - User Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2002-04","conditions":"Seasonal Allergic Rhinitis","enrollment":200},{"nctId":"NCT00641212","phase":"PHASE4","title":"Children, Perennial Allergic Rhinitis (PAR), l-t Growth","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2000-01","conditions":"Perennial Allergic Rhinitis","enrollment":209}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Budecort Aqua","genericName":"Budecort Aqua","companyName":"Eurofarma Laboratorios S.A.","companyId":"eurofarma-laboratorios-s-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Budecort Aqua is an inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors in lung tissue. Used for Allergic rhinitis, Asthma (maintenance therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}